A 2-Stage (Open-Label Followed by Randomized Double-Blind, Placebo-Controlled Stage), Phase 2 Trial of Setmelanotide in Patients With Specific Gene Variants in the Melanocortin-4 Receptor Pathway
Latest Information Update: 21 May 2025
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms DAYBREAK
- Sponsors Rhythm
Most Recent Events
- 14 May 2025 According to a Rhythm Health media release, data from the study were presented at 32nd annual European Congress on Obesity (ECO) and Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE)
- 08 Nov 2024 Status changed from active, no longer recruiting to completed.
- 05 Nov 2024 According to a Rhythm Health media release, encouraging data from this trial will be presented During The Obesity Societys ObesityWeek conference in San Antonio in November 2024.